• Results for the First Quarter 2023

    NOK 82.1. The Vascular business segment continues the positive development and grows at 21.5% in NOK, currency neutral 8.8% growth. The Imaging products grow at 9.4% in NOK, currency neutral decline of 3.7%. Currency neutral…

    Read more
  • Annual Report 2022

    Further supported by several high-quality symposia at the largest heart surgery conferences, we achieved 44 % growth in the imaging product portfolio in 2022. And while steadily penetrating the Cardiac bypass market, we also build…

    Read more
  • Results for the Fourth Quarter and Preliminary Results for 2022

    All major geographical regions drive sales growth. Currency-neutral sales increased by 21.6 % for the quarter and 11.9 % for the year. Currency-neutral sales of own products increase 24.6 % for the quarter and 14.0…

    Read more
  • Capital Markets Day

    See the recording from Medistim's Capital Markets Day on March 21st where two international thought leaders, Professors John. D. Puskas and Pirkka Vikatmaa shared their insights on the future trends in Cardiac and Vascular Surgery…

    Read more
  • Presentation of Medistim’s Q4 and preliminary year-end results 2022

    The financials will be presented via a live webinar on Wednesday, March 1st from 08:00-09:00 (CET).┬áRepresentatives for the company will be Kari Eian Krogstad (CEO), and Thomas Jakobsen (CFO). The recording will be made available…

    Read more
  • Results for the third quarter 2022

    In the third quarter, total revenue ended at MNOK 116.5 (MNOK 102.1), a 14.0% increase. Sales growth is driven by the USA with a currency-neutral sales increase of 18.7 % for the quarter and 24.1…

    Read more
  • Results for the second quarter and first half 2022

    Sales growth is driven by the USA with a currency-neutral sales increase of 28 % for the quarter and 29 % for the first half. Strategic areas of Vascular Surgery and Imaging products show high…

    Read more
  • Results for the First Quarter 2022

    All-time high sales for a quarter ending at MNOK 116.1 (MNOK 102.6), an increase of 13.2%. Sales growth is driven by the USA with a currency-neutral increase of 34.2%. Currency neutral sales of own products…

    Read more
  • Annual Report 2021

    This rebound has continued throughout 2021, and Medistim has experienced strong growth in revenues due to the increase in number of CABG procedures performed. The sales growth was 17.6 % in NOK and operating profit…

    Read more
  • Results for the Fourth Quarter and Preliminary Results for 2021

    All time high sales for a quarter, ending at MNOK 112.7 (MNOK 94.2), an increase of 19.7%. Full year 2021 sales ended at a record of MNOK 427.3 (MNOK 363.1). Currency neutral sales of own…

    Read more